GeneCapture, Inc. is organized around developing diagnostic devices rapidly to detect and identify the nature and source of an infection - typically, less than an hour - using a portable machine with simple sample preparation that does not require the use of enzymatic amplification steps. The firm's approach to disease diagnostics uses rapid RNA-based technology to bring infection detection to the Point of Care; whether thats a hospital bed, an airport, a cruise ship, or a battlefield. Using direct RNA hybridization and optical sensing, the firm's validated pathogen detection, and antibiotic sensitivity test provides rapid results for on-site, real-time decision making.The proprietary technology that underpins the firm's offering could have the potential significantly to impact infection control by providing a Point of Care, inexpensive, rapid diagnosis for pathogens in humans, agriculture and animals. The objective is to bring infection detection to any Point of Care; hospital bed, airport, cruise ship, or battlefield. The effort is to enable health professionals to contain pandemics and provide urgent care in areas ranging from disease stricken countries to international travel.
